Interestingly, the p38 MAPK inhibitor reduced the gene expression levels of TNF-α and other inflammatory cytokines that were increased during the SARS-CoV-2 infection of lung cancer cells in a dose-dependent manner, referring to p38 MAPK as a potential pharmacological target for COVID-19 (Bouhaddou et al., 2020). Here, TNF is linked to COVID-19.